Sign up online today & collaborate
or click here to find out more
Last July, when Federal Reserve Chair Janet Yellen spurred a sell-off in healthcare stocks by saying that valuations in shares of biotech companies looked "stretched," portfolio manager Graham Tanaka saw an opportunity.
After a year-long buying spree, he now has more than a quarter of his $17 million Tanaka Growth & fund portfolio in healthcare companies such as Gilead Sciences Inc, up from just 5 percent at the start of last year.
That bet is paying off: his fund is beating the S&P 500 by about 13 percentage points since the start of the year, putting Tanaka in the top 1 percent of equity fund managers tracked by Morningstar. Even with his big bet on healthcare, he's planning on adding more.For more click here